 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA FRA:NV9M has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it a vastly stronger and more substantial business, according to CEO Dr James Garner. During the quarter, the oncology-focused drug development company saw maiden revenue of A5.3 million and its cash position increased to A19.7 million by the end of March. 